Resistell initiates a research project funded by an independent grant from Pfizer AG

Run in close collaboration with the microbiologists and infectious diseases specialists at the Lausanne University Hospital (CHUV) in Switzerland, the goal of the ongoing clinical study is to assess the sensitivity, specificity, accuracy and time to result of Resistell AST compared to the gold standard methods used at CHUV, namely Kirby-Bauer disc diffusion test and automated Vitek2 system® (bioMérieux). The study focuses on patients admitted to CHUV with bacteremia or sepsis due to Gram-negative bacteria.

Resistell is proud to be a part of SPEARHEAD project which launches to address the silent pandemic of antimicrobial resistance (AMR).

Resistell is proud to be featured in the "Startup Guide Basel Area".

Meet Resistell's team at the Swiss Symposium in Point-of-Care Diagnostics and see live presentation of our technology.